HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of blueberry extract on energetic metabolism, levels of brain-derived neurotrophic factor, and Ca2+-ATPase activity in the hippocampus and cerebral cortex of rats submitted to ketamine-induced mania-like behavior.

Abstract
Bipolar disorder (BD) is a psychiatric disease characterized by mood episodes. Blueberry is rich in bioactive compounds and shows excellent therapeutic potential against chronic diseases. The aim of this study was to evaluate the effects of blueberry extract on behavior, energetic metabolism, Ca2+-ATPase activity, and levels of brain-derived neurotrophic factor (BDNF) in the cerebral cortex and hippocampus of rats submitted to an animal model of mania induced by ketamine. Vehicle, lithium (45 mg/kg, twice a day), or blueberry extract (200 mg/kg), was orally administered to Wistar rats for 14 days. Ketamine (25 mg/kg) or vehicle was administered intraperitoneally, once a day, between the 8th and 14th day. On the 15th day, animals received ketamine or vehicle and were subjected to the open field test. Our results demonstrated that the administration of lithium and blueberry extract prevented ketamine-induced hyperlocomotion (P < 0.01). Blueberry extract attenuated the ketamine-induced reduction in the activity of complex I in the cerebral cortex (P < 0.05). Additionally, the administration of ketamine reduced the activities of complexes I and IV (P < 0.05) and citrate synthase in the hippocampus (P < 0.01). However, blueberry extract attenuated the inhibition in the activity of complex IV (P < 0.01). Furthermore, ketamine reduced the Ca2+-ATPase activity in the cerebral cortex and hippocampus (P < 0.05); however, blueberry extract prevented the change in the cerebral cortex (P < 0.05). There were no significant alterations in the levels of BDNF (P > 0.05). In conclusion, this suggested that the blueberry extract can serve as a potential therapeutic strategy for studies searching for novel therapeutic alternatives for BD patients.
AuthorsLuiza Spohr, Mayara Sandrielly Pereira Soares, Natália Pontes Bona, Nathalia Stark Pedra, Alethéa Gatto Barschak, Rafaela Martins Alvariz, Marcia Vizzotto, Claiton Leoneti Lencina, Francieli Moro Stefanello, Roselia Maria Spanevello
JournalMetabolic brain disease (Metab Brain Dis) Vol. 37 Issue 3 Pg. 835-847 (03 2022) ISSN: 1573-7365 [Electronic] United States
PMID35043268 (Publication Type: Journal Article)
Copyright© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Chemical References
  • Bdnf protein, rat
  • Brain-Derived Neurotrophic Factor
  • Plant Extracts
  • Ketamine
  • Adenosine Triphosphatases
Topics
  • Adenosine Triphosphatases (metabolism)
  • Animals
  • Behavior, Animal
  • Blueberry Plants (metabolism)
  • Brain-Derived Neurotrophic Factor (metabolism)
  • Cerebral Cortex (metabolism)
  • Disease Models, Animal
  • Hippocampus (metabolism)
  • Ketamine (pharmacology)
  • Mania
  • Plant Extracts (metabolism, pharmacology, therapeutic use)
  • Rats
  • Rats, Wistar

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: